“We have made a huge commitment to get our vaccine — and I consider it the best of the best — to the poorest of the world.”
Dr. Gregory Glen, President of Research & Development at Novavax joins the podcast to talk about their COVID-19 vaccine. Like those used for decades to protect against viral infections, such as shingles and hepatitis, Novavax’s COVID-19 vaccine is protein-based. It presents a genuine alternative for those keen to be protected but wary of the newer vaccine technologies, like mRNA.
In this episode, Dr. Glen describes Novavax’s innovative methods, immunity stimulating adjuvant Matrix-M™, and how their vaccine differs from the others available. He reveals the hurdles faced conducting Novavax’s two gold-standard clinical trials amidst the challenging landscape of evolving variants and shares the encouraging data produced.
Currently authorized for use in countries throughout Europe and Asia, and pending emergency use authorization in the United States, Novavax has partnered with the Serum Institute of India to ramp up production. Together they have pledged 1.1 billion COVID-19 vaccine doses to the neediest parts of the world. A move that could, with hope, help accelerate our path out of this pandemic.
01:33 — Elegant and effective: Just what makes the Novovax COVID-19 vaccine unique?
05:43 — Conducting clinical trials amidst the challenging landscape of evolving variants.
11:05 — Strain change strategy: developing a vaccine especially for Omicron.
14:42 — Key partnerships to pledge 1.1 billion doses to the neediest parts of the world.
18:54 — Diversity in gold-standard clinical trials.
21:28 — More than COVID – collaborating to vaccinate against malaria.
25:27 — What is Matrix-M™ adjuvant technology?